Sanofi logoSanofi
multiple sclerosis

Sanofi facing tolebrutinib setback in MS

Sanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS.

Read more
The FIDA principle: A narrow indicator zone is introduced into a capillary under hydrodynamic flow. When the indicator is not bound, a narrow peak is observed at the detector. However, when the indicator is bound by the target analyte, the apparent size increases and a broader peak is observed. This change in size can be used for determine the analyte concentration and interaction.FIDA Biosystems ApS
Financing

Eifo and Fsg back Fida Biosystems with €5m investment

Fida Biosystems ApS has added  €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug discovery.

Read more
Discovery of miRNA drug candidates and uncovering miRNA-mRNA molecular target networkPharmahungary Group
Drug Discovery

miRNA discovery & development platform

Pharmahungary Group (PH) developed miRNAtarget, a miRNA discovery software tool based on miRNA-mRNA molecular networks. PH holds patent families on 4 cardio-protective microRNAs families (protectomiRs) and seeks for co-development partners and/or early stage ­investors. PH also offers its miRNA discovery and development service platform that includes ­efficacy testing from in vitro to large animal models in various therapeutic areas.

Read more
Antoine Papiernik, Chairman & Managing Partner at Sofinnova PartnersSofinnova Partners
Europe

Europe’s moment: We could be the heroes of biotech

Capital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.

Read more
Country ranking concerining the number of industry-sponsored clinical trailsVFA
Clinical studies

German pharma association publishes clinical trial ranking

The German pharmaceutical association vfa has updated its ranking of the best locations for industry-sponsored clinical trials. In Europe, Spain retained its top position in 2024, followed by Australia, Germany, the UK, and France.

Read more
Philippe Van Overeem, founder of Van Overeem Nuclear BVVan Overeem Nuclear BV
Cancer radiopharmaceuticals

RadioMedix expands thorium-228 supply for 212Pb

Radiopharmaceuticals specialist RadioMedix Inc has secured five-year Thorium-228 supply from Van Overeem, strengthening 212Pb production and Targeted Alpha Therapy pipeline development.

Read more
Conference Room at Bayer Co.Lab BerlinBayer Co.Lab
Incubator

Berlin: Why Start-ups Choose Bayer Co.Lab

One year after the inauguration of Bayer Co.Lab — the open workspace for start-ups in Berlin — it is time to take stock. European Biotechnology News Magazine
spoke with tenants and with Dr Ruth Shah, Head of Bayer Co.Lab Berlin, about the concept, the offering, and the feedback Bayer has received so far.

Read more
© Zealand Pharma
Obesity

Zealand pays Chinese OTR US$30m upfront to expand obesity pipeline

Danish Zealand Pharma A/S partners with Chinese start-up OTR Therapeutics Co. Ltd to expand oral obesity pipeline in US$30m upfront deal.

Read more
Eli Lilly Corporate Center, IndianapolisMomoneymoproblemz - wikimedia
Obesity

Lilly‘s retatrutide delivers record weight loss

Lilly’s triple weight loss combination therapy retatrutide has shown 28.7% weight loss in Phase 3, but higher discontinuations vs. tirzepatide and semaglutide.

Read more
San Antonio Breast Cancer SymposiumSan Antonio Breast Cancer Symposium
Breast Cancer

Pfizer presents data for Tukysa in HER2-positive breast cancer

Pfizer’s Tukysa improves progression-free survival in first-line HER2-positive breast cancer, especially in HR-negative patients, with manageable safety. Data were shown at the 2025 San Antonio Breast Cancer Symposium.

Read more